Manufacturer
NOVARTIS PHARMA STEIN AG
Contents
Ranibizumab
Indication
Neovascular (wet) age-related macular degeneration (AMD); visual impairment due to diabetic macular edema (DME), macular edema secondary to retinal vein occlusion (RVO) & choroidal neovascularisation (CNV).
Instruction
0.5 mg as a single intravitreal inj. Interval between 2 doses should be at least 4 wk, then monitor for visual acuity mthly. Wet AMD, DME & RVO Initially, ≥3 consecutive mthly inj may be needed. Thereafter, monitoring & treatment intervals should be based on disease activity. CNV secondary to PM 1 or 2 inj during the 1st year. Accentrix & laser photocoagulation in DME or in branch RVO Administered concomitantly; when given on same day, administer at least 30 min after laser photocoagulation.
Drug interaction
No formal interaction studies have been performed.For the adjunctive use of verteporfin photodynamic therapy (PDT) and ranibizumab in wet AMD, and PM, see Pharmacology: Pharmacodynamics: CLINICAL STUDIES under Actions.For the adjunctive use of laser photocoagulation and ranibizumab in DME and BRVO, see Pharmacology: Pharmacodynamics: CLINICAL STUDIES under Actions and DOSAGE & ADMINISTRATION.In clinical studies for the treatment of visual impairment due to DME, the outcome with regard to visual acuity or central retinal subfield thickness (CSFT) in patients treated with ranibizumab was not affected by concomitant treatment with thiazolidinediones.
Malaysia
